A published preclinical study investigates the potential of combining bone marrow mesenchymal stem cells (BMSCs) with microRNA-181a (miR-181a) to improve therapeutic outcomes in multiple sclerosis (MS). The study, featured in Stem Cell Research & Therapy, focuses on addressing a limitation of current BMSC-based therapies: the instability of their immunosuppressive effects in vivo.
While BMSCs have shown promise in regulating immune responses in such conditions, their therapeutic effects can be short-lived. miR-181a, a microRNA involved in immune cell differentiation, faces similar challenges due to its molecular instability in systemic circulation.
To address this, researchers engineered BMSCs to overexpress miR-181a using a lentiviral vector. This dual-function approach aimed to enhance and stabilize the immunomodulatory properties of the cells. In a mouse model of MS (experimental autoimmune encephalomyelitis, or EAE), the modified cells—referred to as miR181a-BMSCs—demonstrated increased expression of regulatory B cells and T cells, while suppressing inflammatory Th17 cells.
Additionally, exosomes derived from the engineered BMSCs contained higher concentrations of miR-181a, potentially extending its biological activity in vivo. Overall, the combinational therapy appeared to yield stronger and more consistent immunoregulatory effects than standard BMSC treatment alone.
These findings support the concept that integrating gene modulation with stem cell therapy may enhance treatment strategies for autoimmune diseases. Further research, including clinical studies, will be necessary to evaluate its safety and effectiveness in human subjects.
